SEARCH

SEARCH BY CITATION

References

  • 1
    Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycleasatarget for new antiviral therapies. Gastroenterology 2007;132:19791998.
  • 2
    Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011;141:881889.
  • 3
    Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C—a new era in therapy. Aliment Pharmacol Ther 2010;32:1428.
  • 4
    Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010;138:447462.
  • 5
    McCown MF, Rajyaguru S, Kular S, Cammack N, Nájera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009;53:21292132.
  • 6
    Ma H, Leveque V, De Witte A, Li W, Hendricks T, Clausen SM, et al. Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors. Virology 2005;332:815.
  • 7
    Sarisky RT. Non-nucleoside inhibitors of the HCV polymerase. J Antimicrob Chemother 2004;54:1416.
  • 8
    Tomei L, Altamura S, Paonessa G, De Francesco R, Migliaccio G. HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase. Antivir Chem Chemother 2005;16:225245.
  • 9
    Membreno FE, Lawitz EJ. The HCV NS5B nucleoside and non-nucleoside inhibitors. Clin Liver Dis 2011;15:611626.
  • 10
    Fischer G, Gallay P, Hopkins S. Cyclophilin inhibitors for the treatment of HCV infection. Curr Opin Investig Drugs 2010;11:911918.
  • 11
    Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011;54:19561965.
  • 12
    Ghany MG, Strader DB, Thomas DL, Seeff LB; for American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:13351374.
  • 13
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al.; for ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:24052416.
  • 14
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al.; for REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:24172428.
  • 15
    Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al.; for ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:10141024.
  • 16
    Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.; for SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:11951206.
  • 17
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al.; for HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:12071217.
  • 18
    ClinicalTrials.gov. www.clinicaltrials.gov. Accessed January 2012.
  • 19
    Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216224.
  • 20
    Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al.; for PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:18391850.